IL1A and familial Mediterranean fever: According to an Italian study aimed at evaluating the use of IL-1 inhibitors among 475 patients (of whom 111 were aged 16 or less), 86% and 56% of all treatments with ANA and CANA, respectively, were mainly related to adult onset Still’s disease (18.5%), SJIA (13.5%), Behçet’s disease (9.7%), FMF (7.6%), idiopathic recurrent acute pericarditis (5.6%), and TRAPS (5.0%) in the ANA group, and to Behçet’s disease (14.3%), TRAPS (13.3%), FMF (5.7%), and HIDS (3.8%) in the CANA one [73].